TAZ is highly expressed in gastric signet ring cell carcinoma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Yue, Guofeng ^a   Sun, Xia ^a   Gimenez Capitan, Ana ^b   Shen, Jie ^a   Yu, Lixia ^a   Teixido, Cristina ^b   Guan, Wenxian ^a   Rosell, Rafael ^b   Liu, Baorui ^a   Wei, Jia ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; MESSENGER RNA; TAZ PROTEIN; UNCLASSIFIED DRUG; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; DISEASE ASSOCIATION; FEMALE; GASTRIC SIGNET RING CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; VERY ELDERLY; YOUNG ADULT; GENETICS; STOMACH TUMOR;

ADENOCARCINOMA; CARCINOMA, SIGNET RING CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84897866290     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/393064     Document Type: Article

References (29)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 134
2. Cho J. Y., Lim J. Y., Cheong J. H., Park Y.-Y., Yoon S.-L., Kim S. M., Kim S.-B., Kim H., Hong S. W., Park Y. N., Noh S. H., Park E. S., Chu I.-S., Hong W. K., Ajani J. A., Lee J.-S., Gene expression signature-based prognostic risk score in gastric cancer. Clinical Cancer Research 2011 17 7 1850 1857 2-s2.0-79953311879 10.1158/1078-0432.CCR-10-2180
3. Hass H. G., Smith U., Jäger C., Schäffer M., Wellhäußer U., Hehr T., Markmann H.-U., Nehls O., Denzlinger C., Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren's): single-center experience of 160 cases. Onkologie 2011 34 12 682 686 2-s2.0-83755205895 10.1159/000334545
4. Taghavi S., Jayarajan S. N., Davey A., Prognostic significance of signet ring gasrtric cancer. Journal of Clinical Oncology 2012 30 28 3493 3498 10.1200/JCO.2012.42.6635
5. Zhang M., Zhu G., Zhang H., Gao H., Xue Y., Clinicopathologic features of gastric carcinoma with signet ring cell histology. Journal of Gastrointestinal Surgery 2010 14 4 601 606 2-s2.0-77950518980 10.1007/s11605-009-1127-9
6. Li C., Kim S., Lai J. F., Hyung W. J., Choi W. H., Choi S. H., Noh S. H., Advanced gastric carcinoma with signet ring cell histology. Oncology 2007 72 1-2 64 68 2-s2.0-37049007843 10.1159/000111096 (Pubitemid 350249131)
7. Piessen G., Messager M., Leteurtre E., Jean-Pierre T., Mariette C., Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Annals of Surgery 2009 250 6 878 887 2-s2.0-73449102148 10.1097/SLA.0b013e3181b21c7b
8. Kanai F., Marignani P. A., Sarbassova D., Yagi R., Hall R. A., Donowitz M., Hisaminato A., Fujiwara T., Ito Y., Cantley L. C., Yaffe M. B., TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO Journal 2000 19 24 6778 6791 2-s2.0-17744380191 10.1093/emboj/19.24.6778 (Pubitemid 32011671)
9. Murakami M., Nakagawa M., Olson E. N., Nakagawa O., A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proceedings of the National Academy of Sciences of the United States of America 2005 102 50 18034 18039 2-s2.0-29144512222 10.1073/pnas.0509109102 (Pubitemid 41798497)
10. Di Palma T., D'Andrea B., Liguori G. L., Liguoro A., de Cristofaro T., Del Prete D., Pappalardo A., Mascia A., Zannini M., TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Experimental Cell Research 2009 315 2 162 175 2-s2.0-57749190560 10.1016/j.yexcr.2008.10.016
11. Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B. M., Dembowy J., Yaffe M. B., Zandstra P. W., Wrana J. L., TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nature Cell Biology 2008 10 7 837 848 2-s2.0-46049087598 10.1038/ncb1748 (Pubitemid 351927712)
12. Lei Q.-Y., Zhang H., Zhao B., Zha Z.-Y., Bai F., Pei X.-H., Zhao S., Xiong Y., Guan K.-L., TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Molecular and Cellular Biology 2008 28 7 2426 2436 2-s2.0-41149098966 10.1128/MCB.01874-07 (Pubitemid 351429986)
13. Zhou Z., Hao Y., Liu N., Raptis L., Tsao M.-S., Yang X., TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 2011 30 18 2181 2186 2-s2.0-79955638768 10.1038/onc.2010.606
14. Xie M., Zhang L., He C. S., Prognostic significance of TAZ expression in resected non-small cell lung cancer. Journal of Thoracic Oncology 2012 7 5 799 807 10.1097/JTO.0b013e318248240b
15. De Cristofaro T., Di Palma T., Ferraro A., Corrado A., Lucci V., Franco R., Fusco A., Zannini M., TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. European Journal of Cancer 2011 47 6 926 933 2-s2.0-79952986430 10.1016/j.ejca.2010.11.008
16. Yuen H. F., McCrudd C. M., Huang Y. H., TAZ Expression as prognostic indicator in colorectal cancer. PLoS ONE 2013 8 1 54211
17. Zhao D., Zhi X., Zhou Z., Chen C., TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis 2012 33 1 59 67 2-s2.0-84855404337 10.1093/carcin/bgr242
18. Lai D., Ho K. C., Hao Y., Yang X., Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Research 2011 71 7 2728 2738 2-s2.0-79953310106 10.1158/0008-5472.CAN-10-2711
19. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., Inui M., Montagner M., Parenti A. R., Poletti A., Daidone M. G., Dupont S., Basso G., Bicciato S., Piccolo S., The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011 147 4 759 772 2-s2.0-81055140859 10.1016/j.cell.2011.09.048
20. Zimmermann K. C., Sarbia M., Weber A.-A., Borchard F., Gabbert H. E., Schrör K., Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Research 1999 59 1 198 204 2-s2.0-0032893269 (Pubitemid 29062978)
21. Wei J., Costa C., Ding Y., Zou Z., Yu L., Sanchez J. J., Qian X., Chen H., Gimenez-Capitan A., Meng F., Moran T., Benlloch S., Taron M., Rosell R., Liu B., MRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. Journal of the National Cancer Institute 2011 103 20 1552 1556 2-s2.0-80054915400 10.1093/jnci/djr326
22. Pan D., The hippo signaling pathway in development and cancer. Developmental Cell 2010 19 4 491 505 2-s2.0-77957883342 10.1016/j.devcel.2010. 09.011
23. Zhao B., Li L., Lei Q., Guan K.-L., The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes and Development 2010 24 9 862 874 2-s2.0-77951837150 10.1101/gad.1909210
24. Siew W. C., Chun J. L., Guo K., Chee P. N., Lee I., Hunziker W., Zeng Q., Hong W., A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Research 2008 68 8 2592 2598 2-s2.0-42349088170 10.1158/0008-5472.CAN-07-2696 (Pubitemid 351556257)
25. Zhang H., Liu C.-Y., Zha Z.-Y., Zhao B., Yao J., Zhao S., Xiong Y., Lei Q.-Y., Guan K.-L., TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. Journal of Biological Chemistry 2009 284 20 13355 13362 2-s2.0-67649412006 10.1074/jbc.M900843200
26. Bhat K. P. L., Salazar K. L., Balasubramaniyan V., Wani K., Heathcock L., Hollingsworth F., James J. D., Gumin J., Diefes K. L., Kim S. H., Turski A., Azodi Y., Yang Y., Doucette T., Colman H., Sulman E. P., Lang F. F., Rao G., Copray S., Vaillant B. D., Aldape K. D., The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes and Development 2011 25 24 2594 2609 2-s2.0-84255160601 10.1101/gad.176800.111
27. Lim J. Y., Yoon S. O., Seol S. Y., Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World Journal of Gastroenterology 2012 18 30 4037 4043 10.3748/wjg.v18.i30.4037
28. Aoki M., Ishigami S., Uenosono Y., Arigami T., Uchikado Y., Kita Y., Kurahara H., Matsumoto M., Ueno S., Natsugoe S., Expression of BMP-7 in human gastric cancer and its clinical significance. British Journal of Cancer 2011 104 4 714 718 2-s2.0-79951669909 10.1038/sj.bjc.6606075
29. Yoshii M., Tanaka H., Ohira M., Expression of Forkhead box P3 in tumor cells causes immunregulatory function of signet ring cell carcinoma of the stomach. British Journal of Cancer 2012 106 10 1668 1674 10.1038/bjc.2012.141